1,721,008 research outputs found
Arsenic Trioxide, Itraconazole, All-Trans Retinoic Acid and Nicotinamide: A Proof of Concept for Combined Treatments with Hedgehog Inhibitors in Advanced Basal Cell Carcinoma
Full text linkThe treatment of advanced basal cell carcinoma has seen a progressive evolution in recent years following the introduction of Hedgehog pathway inhibitors. However, given the burden of mutations in the tumor microenvironment and lack of knowledge for the follow-up of advanced basal cell carcinoma, we are proposing a possible synergistic therapeutic application. Our aim is to underline the use of arsenic trioxide, itraconazole, all-trans-retinoic acid and nicotinamide as possible adjuvant therapies either in advanced not responding basal cell carcinoma or during follow-up based on Hedgehog pathway. We have analyzed the rational use of these drugs as a pivotal point to block neoplasm progression, modulate epigenetic modification and prevent recurrences
Experimental Pharmacological Management of Psoriasis
No full textElena Campione,1 Terenzio Cosio,1 Monia Di Prete,2 Caterina Lanna,1 Annunziata Dattola,1 Luca Bianchi1 1Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, 00133, Italy; 2Anatomic Pathology, University of Rome Tor Vergata, Rome, 00133, ItalyCorrespondence: Elena CampioneDermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier,1, Rome, 00133, ItalyTel +39.06.20900252Email [email protected]: Psoriasis is a chronic, relapsing, immune-mediated systemic disease. Its pathogenesis is complex and not fully understood yet. Genetic and epigenetic factors interact with molecular pathways involving TNF-α, IL-23/IL-17 axis, and peculiar cytokines, as IL-36 or phosphodiesterase 4. This review discusses the mechanisms involved in the development of the disease, as well as the therapeutic options proposed following the investigation of the inflammatory psoriatic pathways. We performed a comprehensive search using the words “psoriasis” and the newest molecules currently under investigation and approval. From these data, a new scenario in psoriasis is occurring to personalize the therapies - especially systemic ones and those using small molecules – and avoid topical and injectable drugs. We reported the newest therapeutic opportunities, including the inhibitors of Janus kinase/tyrosine kinase 2, phosphodiesterase-4 and IL-36 receptor. Today, more than 20 molecules are under investigation for the treatment of cutaneous psoriasis. Most of them are constituted by small molecules or biologic therapies. This underlines how psoriasis needs systemic therapies, due to its complex pathogenesis and multisystemic involvement.Keywords: psoriasis, janus kinase inhibitors, tyrosine kinase 2 inhibitors, phosphodiesterase 4 inhibitors, IL-36 receptors inhibitor
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Treatment of recalcitrant squamous carcinoma in situ of penis with tapering imiquimod 5–3.75% cream
No full textInfluence of highway traffic flow condition on pollutant emissions of diesel passenger cars using driving simulator
No full textIn the last 20 years the attention of international organizations towards air pollution has been improved, leading to definition of laws and regulations. In order to evaluate strategies and policies, forecasting tools have been adopted by institutions. Currently, the estimation of traffic emissions is based on static models, in which the amount of pollutant is computed as a function of average parameters (average speed).
The well-known traffic increase of the recent years has significantly changed the actual flow conditions, producing a strong rise of interferences. As this facet affects the operating condition of each vehicle, the use of a standard emission model at high traffic interference can lead to some inaccuracies. In such cases, instantaneous emission models introduce deeper capabilities; essentially, the pollutant prediction is directly tied to the engine vehicle operation point in real-like traffic condition. This second modeling approach has been adopted in the current work. A complete lumped parameter vehicle model has been built to be used as a virtual on-road emission/fuel consumption test unit. Investigations have highlighted the dependence of emission level and fuel consumption on drivers’ behavior; indeed, the analysis took advantage of the experiments carried out in the virtual reality laboratory: on a typical highway geometry, three different flow conditions have been simulated. In the present study has been highlighted the relationship between drivers behavior and the emissions of a diesel compact passenger car. Finally, in order to assess the differences between static and instantaneous emission models, a comparative analysis has been carried out
L’uso di strumenti di guida simulata per il calcolo delle emissioni di un’infrastruttura viaria
No full text
- …
